Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
To advance DNA-based therapeutics for Friedreich's ataxia
January 2, 2014
By: Kristin Brooks
Managing Editor, Contract Pharma
Agilis Biotherapeutics and Intrexon Corp. have entered an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich’s ataxia (FRDA), a rare genetic neurodegenerative disease. The companies will explore DNA-based therapeutics to directly target underlying disease mechanisms using tightly-controlled gene therapies for patients with rare inherited diseases such as FRDA. Agilis will employ its Intrexon’s UltraVector platform and RheoSwitch Therapeutic System (RTS) to develop gene therapies and genetically-modified cell therapies for treating FRDA. The collaboration aims to target FRDA employing RTS, a clinically validated inducible gene switch technology to repair or replace the “broken” gene in FRDA and allow increased production of the frataxin protein to alleviate the effects of frataxin deficiency. Current FRDA therapies are primarily focused on symptom relief and there are no FDA-approved drugs to treat the cause of FRDA. FRDA is an inherited disease that results in nervous system damage, problems with movement and early death most often caused by cardiac malfunction. FRDA affects an estimated 5,000 to 10,000 patients in the U.S. “We are thrilled to be working with Intrexon with the hope of providing children and adults affected with rare genetic disorders with promising new treatments,” said George S. Zorich, chief executive officer of Agilis. “We believe Agilis is on the forefront of one of the most promising treatment breakthroughs for Friedreich’s ataxia. I am personally excited to collaborate with the Intrexon team and look forward to developing new transformative therapies together.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !